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Marine microorganisms are rich source for natural products which play important roles in pharmaceutical industry. Over the
past decade, genome-based studies of marine microorganisms have unveiled the tremendous diversity of the producers of natural
products and also contributed to the eﬃciency of harness the strain diversity and chemical diversity, as well as the genetic diversity
of marinemicroorganisms for therapid discovery and generation of new natural products. In themeantime, genomic information
retrieved from marine symbiotic microorganisms can also be employed for the discovery of new medical molecules from yet-
unculturable microorganisms. In this paper, the recent progress in the genomic research of marine microorganisms is reviewed;
newtoolsofgenomeminingaswellastheadvanceintheactivationoforphanpathwaysandmetagenomicstudiesaresummarized.
Genome-based research of marine microorganisms will maximize the biodiscovery process and solve the problems of supply and
sustainability of drug molecules for medical treatments.
1.Introduction
The marine environment covers more than 70% of the
Earth’s surface and has been proven to be a rich source for
both biological and chemical diversity. Marine natural pro-
ducts have become fascinating targets for biologists and
chemists for discovery of lead compounds for clinical de-
velopment for the past ﬁve decades [1–10]. Marine microor-
ganisms comprise an important group of natural product
producers, and the natural products isolated from marine
microorganisms presented diverse activities, such as antibac-
terial, antifungal, anticancer, and antiviral activities. Of the
major producers of useful natural products, marine acti-
nobacteria are especially notable for the capability of pro-
ducing diverse useful natural products [5–7], and marine
cyanobacteria are also an important group of bioactive met-
abolites [5]. Currently 13 marine-derived compounds are re-
ported in clinical development, and those belong to the au-
thenticorderivativesofmarinenaturalproductsofmicrobial
origin and are listed in Table 1, and the structures are dis-
played in Figure 1. Of these compounds, soblidotin (TZT
1027), the synthetic derivative of dolastatin 10, was isolated
from the marine cyanobacterium Symploca sp. VP642 from
Palau, and the synthesis of plinabulin (NPI-2358) was in-
spired by halimide and phenylahistin, the former of which
was isolated from a marine fungus Aspergillus sp. CNC-139.
The structures of other interesting compounds with novel
structures or potent activities can be retrieved from the re-
cent literatures and review papers [8–17].
Although natural products embrace a wide range of enti-
tiessuchasbiomaterialsandbiocatalystsaswellasbiocontrol
agents other than drug molecules, due to space limitation, in
this paper, most of the cited natural products focused upon
are compounds with the potential to be developed as drugs
and used in medical treatments. Taking the advantage of
established microbial cultivation technology, the promising
natural products identiﬁed from marine microorganisms
provide great potential to solve the supply and sustainability
problem of useful drugs to cure human diseases.
High-throughput screening (HTS) of drug molecules de-
mands abundant diversity of the compound libraries to get
more hits for drug discovery. To combat the emergence of
drug-resistant pathogens, as well as to improve the eﬃcacy
and safety of medical treatment, new drug leads are urgently
needed. The key point of improving the success of natural2 Evidence-Based Complementary and Alternative Medicine
Table 1: Active natural products isolated from marine microorganisms.
Metabolites Source Activity Reference Clinical status
Soblidotin (TZT1027)
Synthetic derivative of dolastatin 10
isolated from marine cyanobacterium
Symploca sp. VP642
Anticancer [12] Phase III
Plinabulin (NPI-2358) Synthetic analog of halimide isolated from
the marine fungus Aspergillus sp. CNC-139 Anticancer [13] Phase II
Bryostatin 1
Identiﬁed from bryozoan and also marine
symbiotic bacteria Candidatus Endobugula
sertula
Anticancer,
Anti-Alzheimer [14] Phase I
Marizomib (salinosporamide A, NPI-0052) Marine actinobacteria Salinispora arenicola Anticancer [15] Phase I
Compound 4 (curacin A synthetic derivative) Curacin A was isolated from the marine
cyanobacterium Lyngbya majuscula Anticancer [16] Preclinical
product screening and development is to improve the diver-
sity and the size of natural product library for new drug dis-
covery. In this paper, the recent progress in the genomic re-
search for natural compound discovery is summarized, with
the focus on the important roles of genetic diversity deduced
from genome mining on new drug discovery.
2. GenomicSequencingof Natural-Product-
ProducingMicroorganisms
Genomic sequencing of microorganisms in the recent years
has unveiled unprecedented insights into the biosynthetic
potential of microbial cells, and thus the discovery of natural
products has entered into the new postgenomic era. The
genomic sequencing data of various living organisms have
been accumulating rapidly in recent years. According to the
Genomes On Line Database (GOLD), there are 5831 genome
sequencing projects registered in GOLD, while according to
the last update (April 11, 2011), 10298 genome projects are
documented currently in GOLD (http://www.genomeson-
line.org), of which 1674 complete genomes are regis-
tered. And in the mean time, 204 archaeal, 6087 bac-
terial,and2003eukaryalgenomeprojectsareongoing,which
are double of those reported in 2009 [18] .T h es a m ec a s ei s
the genome project numbers in 2009 comparing with those
in 2007 [19]. Genome sequencing projects supported by the
Gordon and Betty Moore Foundation resulted in the release
of about 150 marine bacterial genomes [20]. Draft or com-
plete genomic sequences of more than 35 marine cyanobac-
terial strains of six diﬀerent species have been released, and
some gene clusters for polyketide and nonribosomal peptide
biosynthesis were identiﬁed [21]. It can be anticipated that
more marine microbial genomic sequences will be available
in the near future, and more relevance of natural product bi-
osynthesistothemicrobialgenomeswillbedisclosed.Forin-
stance, the genomes of marine Nocardiopsis sp. strain TFS65-
07 and marine-derived fungus strain Aspergillus sp. MF297-2
were reported to be sequenced, and studies on the biosyn-
thesis of thiopeptide antibiotic TP-1161 and prenylated in-
dole alkaloids, stephacidin and notoamide metabolites, were
subsequently guided by the bioinformatics analysis of gene
clusters located in these genomes [22, 23]. Despite the fact
that comparing to the studies on terrestrial species and
strains, genomic studies of marine-derived microorganisms
arestillwellperformed,theknowledgeaccumulatedfromthe
terrestrial microorganisms can be used also in the marine-
derived strains. Actinobacteria are major producers of var-
ious useful antibiotics and antitumor agents. In the below
section, I gave some examples on the investigations on
the genomes of some model or natural-product-producing
strains, which will shed light on their marine-derived coun-
terparts.
Streptomyces is the largest genus of actinobacteria, and,
species of streptomycetes are major producers of antibiotics
which have wide range of utilities in medical treatments and
agricultural applications. The ﬁrst genomic sequencing of
the model streptomycete, Streptomyces coelicolor A3 [2], was
reported in 2002 [24], and the genome contains about 31
biosynthetic gene clusters that were predicted to contribute
to the biosynthesis of secondary metabolites, which are the
major source of bioactive natural products. Surprisingly,
only half a dozen of these secondary metabolites in S. coeli-
color have by that time been identiﬁed, which implies that
microbial cells can produce much larger chemical diversity
than previously anticipated. Later on, the genome sequence
of S. avermitilis was also reported [25], followed by the
blooming uncover of genomic sequences of various antibi-
otic producers [26–31].
The genome sequence of the ﬁrst seawater-requiring
marine actinomycete, Salinispora tropica, was reported [26].
Bioinformatics analysis revealed that this marine bacterial
species owns a large proportion of genes (about 9.9%) re-
sponsible for natural product biosynthesis, while the cor-
responding numbers in S. coelicolor and S. avermitilis are
4.5% and 6%, respectively [32]. The genome of S. tropica
contains amazingly large size of genes (516Kb) dedicated
to polyketide synthase (PKS) and/or nonribosomal peptide
synthetase (NRPS) biosynthesis, which are megasynthases
that are responsible for many active natural product biosyn-
thesis and are especially popular tools for combinational bi-
osynthesis [33–35]. The majority of the gene loci are novel,
indicating that S. tropica has great potential to produce
novel natural products and that the biosynthetic potential
of this species, like that of many other actinomycetes that






















































Figure 1: Structures of the marine microbial-derived compounds in clinical development.
that has been observed by cultivation and chemical analysis
[26], which provided basis for mining of these novel genetic
sources for new natural products.
3. ImportantRoles of Genetic
Studies to Maximize the Diversityfor
Natural Product Discovery
Although natural products from marine microorganisms
have already widened the spectrum of chemical diversity, in-
creasing the diversity of natural compounds is still the pre-
requisite for HTS to get enough new hits for drug discov-
ery. And in the meantime, the classical activity-based screen-
ingisincreasinglychallengedbyrepeateddiscoveryofknown
compounds, as well as the limitation of available assay meth-
ods. Therefore, new techniques are needed to maximize the
diversity of natural products for the discovery of new ther-
apeutic agents, not only to increase the eﬃcacy and decrease
the toxicity, but also to combat the emergence of drug resist-
ance.
The development of genomic sequencing techniques as
well as the bioinformatics tools in recent years has profound
inﬂuenceonthediscoveryofnewdrugs.Nowadaysitismuch
easier to have the genome of the interested organisms se-
quenced, especially for relatively small genomes of micro-






























Figure 2: Important tools to maximize the diversity for new drug discovery.
subsequent genome mining of microorganisms have pro-
vided new insights in the biosynthetic potential of the cells,
and thus the studies of marine natural products have entered
into the new postgenomic era. There is an increasing trend
to expand the studies on the chemical diversity of natural
products from bioassay-based screening to genetic diversity
studies, from the studies of natural diversity to creation and
utilization of recombinant diversity (e.g., to use genetic tools
to produce new “unnatural” natural products), and in the
meantime, it is well accepted that the chemical diversity and
genetic diversity not only exist in diﬀerent microbial species,
but also exist in the diﬀerent strains in one species [36].
Therefore, the chemical diversity for useful natural products
can be maximized by the integration of genomic research
and genetic engineering with the eﬀorts of chemists. The
important strategies to maximize biodiversity of marine nat-
ural products are illustrated in Figure 2, and will be depicted






clustered in the bacterial or fungal genomes to form gene
clusters, which include the genes encoding biosynthetic en-
zymes, as well as genes responsible for regulation and re-
sistance [37]. This genetic feature has not only greatly facil-
itated the molecular cloning and characterization of the bio-
syntheticgenes,buthasalsoprovidedbasisforthegeneration
of novel compounds through combinational biosynthesis.
Traditionally, to identify and isolate the gene cluster for
natural product biosynthesis, knowledge on the chemical
structures of the compounds must be obtained prior to the
genetic studies. However, this “compound-to-gene” route is
facing challenges in that (1) the cultivation media and con-
ditions have great impact on the searching of the chemicals;
therefore, a lot of eﬀorts have to be made to test diﬀerent
media and cultivation parameters; (2) the bioassay-based
screening results in the rediscovery of known compounds
from the screening of natural products; (3) the elucidation
of complex structures; (4) the isolation of the natural pro-
ducts is hampered by low production yields and complex
puriﬁcation procedures.
In the recent years, more and more studies have focused
on the “from genetics-to-chemistry” route for natural prod-
uct research, that is, to use gene-based screening strategy to
study the biosynthetic potential of the microbial strains, fol-
lowed by molecular cloning experiments and chemical puri-
ﬁcations [38, 39]. A good example is the studies on the
identiﬁcation of active halogenated compounds from 550
randomly selected actinomycetes based on the conserved se-
quences from diverse halogenase genes. Using this “genome-
based” strategy, novel halogenase genes were identiﬁed and
novel halometabolites were isolated by the cloning of related
gene cluster in heterologous host [38]. We used the same
strategy to screen the marine actinobacteria strain library
in our lab and isolated a gene cluster putatively involved
in the biosynthesis of glycopeptide antibiotics. Furthermore,
the genomic sequence of a new marine-derived Streptomyces
sp. S187 was obtained, and bioinformatics analysis guided
the identiﬁcation of the gene cluster responsible for a new
glycopeptide antibiotic (unpublished data). Genome scan-
ning is another successful approach, in which the random
genome sequence tags (GSTs) prepared from the genomic
DNA library are screened using degenerate primers to iden-
tify the gene cluster, and the products of the gene cluster
can be subsequently searched using various genomics-guid-
ed strategies [40, 41], which will be detailed in the fol-
lowing section. Using this “gene-to-compound” strategy,
screening of a large strain library can be rapidly focused on
small group of strains with high possibility to produce new
compounds. However, the success of this strategy is depen-
dent on multifaceted factors, including the selection of target
genes for genome-based screening, the design of suitable
degenerate primers, the quality of template DNA (especiallyEvidence-Based Complementary and Alternative Medicine 5
environmental DNA), PCR conditions, and sequence degen-
eracy, and thus is limited to the detection of chemical diver-
sities with diverse structures.
5. Genome Miningof MicrobialNatural
Product Producers
Although the cost of genome sequencing is declining, it is
still not aﬀordable for every lab for natural product research.
Two questions may arise concerning the whole genomic
sequencing.Whydoweneedtoknowallthesequencesonthe
genome? What can we do next after obtaining the genomic
sequence?
To answer the ﬁrst question, it is well accepted that the
genetic loci in the genome can be roughly grouped by genes
involved in primary metabolism and genes involved in sec-
ondarymetabolism. Becausenotallgenesareexpressedinall
the conditions, the chemical analysis of the cultivation broth
under certain conditions cannot fully explore the biosyn-
thetic potential of the cells. Furthermore, not all genes can
be ﬁshed out by gene-based screening using degenerate PCR;
therefore, sequencing the genome can fully access the genetic
lociresponsiblefornaturalproductbiosynthesis.Atthesame
time, genetic loci involved in primary metabolism are also
tightly linked to the biosynthesis of natural product by pro-
viding precursors and cofactors [42]; therefore, the produc-
tion of natural products requires the balanced interaction of
metabolic network of both primary metabolism and sec-
ondary metabolism. Knowing the genomic sequence is the
prerequisite to understand and harness the diversity of the
natural product producers. The availability of genomic se-
quence also enables the studies of natural product producer
using systems biological approaches, which are exempliﬁed
by the metabolome studies [43] and transcriptome studies
[44]i nS. coelicolor.
The answer to the second question relies on the rapid
development of tools for genome mining, which were pre-
sented in several excellent reviews elsewhere [45–51]. Several
strategies for genome mining for novel natural products
identiﬁcation are summarized below with the addition of
recent reports:
(1) Genome-Guided Structural Prediction of the Products and
Target Isolation. As indicated above, the polyketides and
nonribosomal peptides are synthesized by modular PKS or
NRPS system, and extensive knowledge has been accumu-
lated on the relationship between the structures of these
compounds and the organization of the multienzymes. Suc-
cessful mining of ribosomally synthesized peptides has also
b e e nr e p o rt e da n ds u m m a r i z e d[ 51]. Bioinformatics analysis
of these groups of genes thus can give important insight
into the structural features of the biosynthetic products. The
genome-guided discovery of salinilactam A in marine acti-
nomycete S. tropica strain CNB-440 is one good example
[27]. Initial bioinformatises analysis indicated that the slm
gene cluster codes for polyene macrolactam polyketide, and
investigation of the fermentation broth using characteristic


























Figure 3: Structures of salinilactam A and salinosporamide K
discovered by genome mining.
of structural fragments of salinilactam A series compounds.
Inspection of the structure fragments suggested that salini-
lactam A was derived from a PKS with at least 10 extension
modules. This information was useful to help resolve and
properly assemble the repetitive DNA sequences associated
with the slm PKS, which was used in combination of partial
NMR-based structural fragments to accurately predict the
gross chemical structure of salinilactam A. What is more,
bioinformatics analysis also assisted in the correction of the
initial assignment of the C-28 methyl group complicated by
overlapping oleﬁnic NMR signals. The salinilactam A struc-
ture was later veriﬁed by comprehensive NMR analyses of
the puriﬁed natural product to conﬁrm the bioinformatics-
based total structure assignment.
In another recent report, salinosporamide K was discov-
ered by comparative genomic analysis of “S. paciﬁca”w i t h
that of S. tropica [52]. A truncated biosynthetic gene cluster
was identiﬁed in the draft genome of “S. paciﬁca”, which is
related to the 41kb gene cluster in S. tropica for salinospo-
ramide A biosynthesis, but the genes coding for the enzymes
in the chloroethylmalonyl-CoA pathway are absent in “S.
paciﬁca.” This information guided the isolation of salinospo-
ramide K, which structurally resembles salinosporamide A
[26].
The structures of salinilactam A and salinosporamide K
described above were presented in Figure 3.
(2) Comparative Metabolic Proﬁling of the Mutants with the
Addition or Inactivation of the Biosynthetic Genes. Biosyn-
thetic gene clusters that are related to the production of yet-


























Figure 4: Structures of MMF1, 3-formyl-L-tyrosine-L-threonine
dipeptide and 3-formyl-L-tyrosine.
The biosynthetic genes in the orphan gene cluster can be
inactivated by deletion or disruption, and the comparison
of the metabolic proﬁling using HPLC or LC-MS of the
mutant with that of the wild type strain will identify the
product of the gene cluster. The discovery of coelichelin in
S. coelicolor is the early example in which this approach was
employed [53]. Alternatively, the biosynthetic gene clusters
can be heterologously expressed in a well-characterized
“clean” host with no background production of similar
metabolites, and the comparative metabolic proﬁling will
help to identify the novel products. The 5 new 2-alkyl-4-
hydroxymethylfuran-3-carboxylic acids termed as Mm fu-
rans (MMFs), which are new autoinducers to regulate anti-
biotic production, were discovered by this heterologous
expression approach [54]. In a recent report, a gene cluster
containing ATP-grasp enzymes identiﬁed by genome mining
of the marine gamma proteobacterium Pseudoalteromonas
tunicata D2 was overexpressed in E. coli, which led to the iso-
lation of two new metabolites, 3-formyl-L-tyrosine-L-thre-
onine dipeptide and 3-formyl-L-tyrosine [55]. This work
emphasized the studies of smaller pathways (comparing to
PKS and NRPS) employing less familiar biosynthetic strate-
gies for the discovery of novel natural products. The struc-
tures of one Mm furans (MMF1), 3-formyl-L-tyrosine-L-
threonine dipeptide, and 3-formyl-L-tyrosine were shown in
Figure 4.
(3) Activation of the Biosynthetic Genes by Manipulation of
Regulatory Genes. The failure of producing certain natural
products can be attributed to the poor expression or silence
of the biosynthetic gene cluster. Therefore, overexpression
of the regulatory genes, either pathway-speciﬁc regulatory
genes or global regulatory genes, can lead to the production
of novel compounds. One example is the discovery of aspyri-
dones in Aspergillus nidulans. Overexpression of the putative
pathway-speciﬁc regulatory gene located in the silent gene
cluster resulted in the identiﬁcation of the novel hybrid PKS-
NRPS product aspyridone [56]. Alternatively, the promoter
of the pathway-speciﬁc regulatory gene can be replaced by
strong constitutive promoter, so that the expression of reg-
ulatory gene can be deregulated by repression.
On the other hand, some regulatory genes can also exert
inhibitory eﬀect on the production of certain compounds;
in this case, the deletion of such regulatory genes readily re-
sults in the activation of silent pathways and production of
novel compounds. In a recent report, a new yellow-pig-
mented secondary metabolite was observed in S. coelicolor
after deleting a putative pathway-speciﬁc regulatory gene
(scbR2) that encodes gamma-butyrolactone receptor protein
[57]. This strategy can be used for the discovery of novel
natural products from marine microorganisms, although no
known literature in this aspect has been reported so far.
Other strategies for genome mining including genomiso-
topic studies and in vitro reconstitution of biosynthetic en-
zymes were described in reviews elsewhere [58, 59]. It can
be predicted that genome mining of marine microorganisms
will unveil the tremendous diversity of natural products
produced by microorganisms. What is more, it should be
mentioned that only 1% of the microbial community is
estimated to be culturable in lab conditions [60–62], point-
ingouttheimportancetheareaofbiodiversityresearchinthe
yet “unculturable” microorganisms, which will be addressed
in the following section.
6. Metagenomic Studies of “Unculturable”
Marine Microorganisms
Marine symbiotic microorganisms are rich source of active
natural products and are thought in some cases to be the
true producers of potent drug candidates instead of the
marine invertebrate including sponges, tunicates, and bry-
ozoans [63]. Shotgun sequencing of the environmental ge-
nome in the seawater samples collected from the Sargasso
Sea near Bermuda also revealed tremendous diversity of the






















































Figure 6: Combination of genome mining with classical activity-based screening for natural product discovery, generation, and
hyperproduction.
whichunveiled148previouslyunknownbacterialphylotypes
and 1.2 million previously unknown genes. However, the
majority of the marine symbionts and 99% of the microbial
population in environment are diﬃcult to grow or are slow-
ly growing as pure culture. To fully access the valuable
chemical diversity and explore the biosynthetic potential
of all the microbial communities, the environmental DNA
(eDNA) is extracted directly from a given environment, and
packed into vectors, following by transformation to various
hosts, including E. coli and Streptomyces lividans.C l o n e
libraries are produced independently of the host cultivation
or fermentation and then subjected to sequence-based
screening or function-based screening. This cultivation-in-
dependent approach is termed metagenomics. During the
past decade, many successful metagenomic studies have been
reported. Onnamides and theopederins are antitumor pol-
yketides produced by an uncultured Pseudomonas sp. sym-
biont of marine sponge Theonella swinhoei. Biosynthesis
genes of onnamides and theopederins were isolated from the
metagenome of the marine sponge, and bioinformatics anal-
ysisofthebiosyntheticgenesstronglyindicatedaprokaryotic
origin, suggesting that these potent antitumor agents may be
produced by the symbiotic bacteria [65]. An entire putative
gene cluster responsible for the biosynthesis of bryostatin,
which has been evaluated for the treatment of various
leukemias, ovarian cancers, and prostate cancers, has been8 Evidence-Based Complementary and Alternative Medicine
implicated to be produced by a symbiotic bacteria, Candi-
datus Endobugula sertula from the marine bryozoan [66].
In another study, gene cluster for the biosynthesis of potent
antitumor agent psymberin was isolated from the metage-
nomic library of marine sponge Psammocinia aﬀ. Bulbosa
[67]. Combining with the research development in heterolo-
gous expression [68], active compounds can be produced in
large quantities by overexpressing the biosynthetic gene clus-
ters isolated from metagenomic libraries in the heterologous
hosts, which will solve the supply and sustainability problem
of the precious compounds produced by marine symbionts
and the yet “unculturable” marine microorganisms.
The structures of some compounds studied by metage-
nomic analysis were presented in Figure 5.
7. Updating Tools for Exploration of
Diversitiesof NaturalCompounds
Exploration of the diversity of marine natural products is
greatly promoted by various genome-based strategies de-
scribed in this paper, and new chemical structures and novel
bioactivities unveiled by these methods are complementing
the traditional bioassay-guided studies. However, as indi-
cated by Gl¨ ockner and Joint [69], the success of the genome-
basedmethods is largelydependenton the accuracyofbioin-
formatics analysis, and the bioinformatics tools are often
the limiting factor. Researchers are now developing various
b i o i n f o r m a t i c st o o l ss u c ha sC l u s t S c a n[ 70], NP.searcher
[71], SBSPKS [72], to name a few, for the analysis of PKS
or NRPS modular sequences and structure predictions.
On the other hands new tools in the detection of natural
products are continuously being developed to explore the
chemical diversity of microbial natural products. The imag-
ing mass spectrometry (IMS) tools were used to visualize
the spatial distribution of secondary metabolites produced
by marine cyanobacteria [73], providing information for
dereplication and discovery of novel natural products. The
PrISM (Proteomic Investigation of Secondary Metabolism)
approach employs mass-spectrometry-based proteomics to
localize expressed PKS or NRPS clusters, which resulted in
the discovery of new NRPS gene cluster in Bacillus strain
NK2018 [74]. Single-cell genomics approach was used to
study the lifestyle of marine symbiotic bacteria, Poribacteria
[75], and this strategy also holds promise in studying the
biosynthetic potential of unculturable microorganisms in
the near future. All these updated bioinformatics tools and
detection tools can be combined to facilitate new marine
natural products.
The exploration of the diversity of marine microorgan-
isms using the combined classical activity-based screening
with the genome mining in both the culturable and uncul-
turable microorganisms is presented in Figure 6.
8. Conclusion andProspects
Recent years have witnessed the exponentially increasing ge-
nome sequencing information, and genome mining analyses
have revealed tremendous capability of marine microor-
ganisms to produce active natural products as therapeutic
agents.Studiesonthebiosyntheticmachineryandregulatory
mechanisms of natural product biosynthesis will greatly
maximize the diversity exploration of marine natural prod-
ucts. Nowadays the diversity studies of natural products have
been shift from pure chemical analysis to the combination of
genetic manipulations and chemical synthesis, and the di-
versity of natural products can be further enlarged by ge-
netic engineering of biosynthetic genes. Genomic research
of marine microorganisms will have great impact on the
discovery of novel natural products for medical treatments
and will contribute to eﬃcient drug discovery from marine
environment.
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